Figure 4: SSAO inhibitors do not alter CFA-evoked neutrophil MPO-activity and plasma extravasation. | Scientific Reports

Figure 4: SSAO inhibitors do not alter CFA-evoked neutrophil MPO-activity and plasma extravasation.

From: Analgesic and Anti-Inflammatory Effects of the Novel Semicarbazide-Sensitive Amine-Oxidase Inhibitor SzV-1287 in Chronic Arthritis Models of the Mouse

Figure 4

Representative (A) bioluminescence images showing neutrophil MPO-activity and (C) fluorescence images demonstrating plasma protein extravasation in the tibiotarsal joints of mice treated with SzV-1287 and LJP-1207 (20 mg/kg/day i.p. every day during the 21-day experimental period) in comparison with the vehicle. Quantitative analysis of (B) bioluminescence and (D) fluorescence intensity in the ankle joints 2 and 6 days after CFA administration. Data are shown as means ± S.E.M. of n = 6 mice/group, ##p < 0.01, ###p < 0.001 (vs. respective contralateral ankle joint); one-way ANOVA followed by Bonferroni’s multiple comparison test.

Back to article page